It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
It is unclear as to whether Wilms’ tumor 1-associated protein (WTAP) promotes or suppresses breast cancer. This immunohistochemistry analysis explored levels of WTAP expression in 347 cases of breast cancer and analyzed the relationship between WTAP expression and the clinicopathological characteristics and prognosis of breast cancer patients. The rate of high WTAP expression was significantly higher in breast cancer tissue than in adjacent normal breast tissue (37.5% vs 0.0%; P < 0.001). WTAP expression was positively associated with tumor size and grade, and negatively associated with axillary lymph node metastasis, estrogen and progesterone receptor status. Rates of high WTAP expression were 66.1% in triple-negative breast cancer (TNBC) tissue and 31.3% in non-TNBC tissue. In multiple logistic regression analysis, independent predictors of WTAP expression in breast cancer included larger tumor size (odds ratio = 1.907; 95% confidence interval: 1.185–3.067; P = 0.008), lymph node metastasis (0.597; 0.373–0.956; P = 0.032) and TNBC status (3.735; 2.056–6.784; P < 0.001). No clear relationship was observed between patient prognosis and WTAP expression. We suggest that WTAP expression is upregulated in breast cancer and appears to both promote tumor growth and inhibit lymph node metastasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Affiliated Dongyang Hospital of Wenzhou Medical University, Department of Pathology, Dongyang, People’s Republic of China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)
2 China Medical University, Graduate Institute of Basic Medical Science, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Department of Pharmacology, School of Medicine, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); Asia University, Department of Biotechnology, College of Health Science, Taichung, Taiwan (GRID:grid.252470.6) (ISNI:0000 0000 9263 9645)
3 Affiliated Dongyang Hospital of Wenzhou Medical University, Department of Medical Oncology, Dongyang, People’s Republic of China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)
4 Affiliated Dongyang Hospital of Wenzhou Medical University, Department of Surgical Oncology, Dongyang, People’s Republic of China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)